The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia

Haematologica

Volumn 93, Issue 12, 2008, Pages 1797-1805

  Santamaría, Carlos ^a   Chillón, María Carmen ^a   García Sanz, Ramón ^a,b   Balanzategui, Ana ^a   Sarasquete, María Eugenia ^a   Alcoceba, Miguel ^a   Ramos, Fernando ^c   Bernal, Teresa ^d   Queizán, José Antonio ^e   Peñarrubia, María Jesús ^f   Giraldo, Pilar ^g   San Miguel, Jesús F ^a,b   Gonzalez, Marcos ^a,b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c Complejo Hospitalario de Leon ^*

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL GENERAL DE SEGOVIA   (Spain)

^f HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

Author keywords

Acute promyelocytic leukemia; PRAME; Real time quantitative PCR

Indexed keywords

CD135 ANTIGEN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; BONE MARROW; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DISEASE MARKER; DNA SYNTHESIS; FEMALE; FOLLOW UP; FUSION GENE; GENE; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREFERENTIALLY EXPRESSED ANTIGEN OF MELANOMA GENE; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; RECURRENT DISEASE; RNA EXTRACTION; SURVIVAL RATE; SURVIVAL TIME;

ANTIGENS, NEOPLASM; BONE MARROW; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; POLYMERASE CHAIN REACTION; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 57349085670     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.13214     Document Type: Article

References (37)

1. Ikeda H, Lethe B, Lehmann F, van Baren N, Baurain JF, de Smet C, et al. Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. Immunity 1997;6:199-208.
2. Epping MT, Bernards R. A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. Cancer Res 2006;66:10639-42.
3. van Baren N, Chambost H, Ferrant A, Michaux L, Ikeda H, Millard I, et al. PRAME, a gene encoding an antigen recognized on a human melanoma by cytolytic T cells, is expressed in acute leukaemia cells. Br J Haematol 1998;102:1376-9.
4. Greiner J, Schmitt M, Li L, Giannopoulos K, Bosch K, Schmitt A, et al. Expression of tumor-associated antigens in acute myeloid leukemia: implications for specific immunotherapeutic approaches. Blood 2006;108:4109-17.
5. Steinbach D, Hermann J, Viehmann S, Zintl F, Gruhn B. Clinical implications of PRAME gene expression in childhood acute myeloid leukemia. Cancer Genet Cytogenet 2002;133:118-23.
6. Paydas S, Tanriverdi K, Yavuz S, Disel U, Baslamisli F, Burgut R. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects. Am J Hematol 2005;79:257-61.
7. Greiner J, Ringhoffer M, Taniguchi M, Li L, Schmitt A, Shiku H, et al. mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies. Int J Cancer 2004; 108:704-11.
8. Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002;138:89-91.
9. Paydas S, Tanriverdi K, Yavuz S, Seydaoglu G. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature. Leuk Res 2007;31:365-9.
10. Oberthuer A, Hero B, Spitz R, Berthold F, Fischer M. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome. Clin Cancer Res 2004;10:4307-13.
11. Neumann E, Engelsberg A, Decker J, Storkel S, Jaeger E, Huber C, et al. Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? Cancer Res 1998;58:4090-5.
12. Steinbach D, Schramm A, Eggert A, Onda M, Dawczynski K, Rump A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res 2006;12:2434-41.
13. Matsushita M, Ikeda H, Kizaki M, Okamoto S, Ogasawara M, Ikeda Y, et al. Quantitative monitoring of the PRAME gene for the detection of minimal residual disease in leukaemia. Br J Haematol 2001;112:916-26.
14. Tajeddine N, Millard I, Gailly P, Gala JL. Real-time RT-PCR quantification of PRAME gene expression for monitoring minimal residual disease in acute myeloblastic leukaemia. Clin Chem Lab Med 2006;44:548-55.
15. Sanz MA, Martin G, Rayon C, Esteve J, Gonzalez M, Díaz-Mediavilla J, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999;94:3015-21.
16. Sanz MA, Martin G, Gonzalez M, Leon A, Rayon C, Rivas C, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004;103:1237-43.
17. van Dongen JJ, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RTPCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 1999;13:1901-28.
18. Gabert J, Beillard E, van der Velden V, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003;17:2318-57.
19. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-ΔΔ C(T)) method. Methods 2001;25:402-8.
20. Santamaria C, Chillon MC, Fernandez C, Martin-Jimenez P, Balanzategui A, Garcia-Sanz R, et al. Using quantification of the PMLRARα transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia. Haematologica 2007;92:315-22.
21. Beillard E, Pallisgaard N, van der Velden V, Bi W, Dee R, van der Schoot E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQPCR) - a Europe Against Cancer program. Leukemia 2003;17:2474-86.
22. Chillon MC, Fernandez C, Garcia-Sanz R, Balanzategui A, Ramos F, Fernandez-Calvo J, et al. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J 2004;5:239-46.
23. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326-35.
24. Kaplan EL. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
26. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with alltrans retinoic acid: result of the randomized MRC trial. Blood 1999;93:4131-43.
27. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002;100:4298-302.
28. Lo-Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999;94:12-22.
29. Ades L, Sanz MA, Chevret S, Montesinos P, Chevallier P, Raffoux E, et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood 2008;111:1078-84.
30. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R, et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004;350:1605-16.
31. Epping MT, Wang L, Edel MJ, Carlee L, Hernandez M, Bernards R. The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling. Cell 2005;122:835-47.
32. Steinbach D, Pfaffendorf N, Wittig S, Gruhn B. PRAME expression is not associated with down-regulation of retinoic acid signaling in primary acute myeloid leukemia. Cancer Genet Cytogenet 2007;177:51-4.
33. Tajeddine N, Gala JL, Louis M, Van SM, Tombal B, Gailly P. Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res 2005;65:7348-55.
34. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005;105:3019-25.
35. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 2003;102:2746-55.
36. Grimwade D, Lo-Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002;16:1959-73.
37. Sanz MA, Lo-Coco F, Martin G, Avvisati G, Rayon C, Barbui T, et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000;96:1247-53.